Abstract
Background Tanzania is currently implementing therapeutic efficacy studies (TES) in areas of varying malaria transmission intensities as per the World Health Organization’s (WHO) recommendations. In TES, distinguishing reinfection from recrudescence is critical for the determination of antimalarial efficacy. Recently, the WHO recommended genotyping polymorphic coding genes (msp1, msp2, and glurp) and highly polymorphic neutral microsatellites in Plasmodium falciparum to adjust the efficacy of antimalarials in TES. This study assessed the polymorphisms of six neutral microsatellite markers and their potential use in TES, which are routinely performed in Tanzania.
Methods P. falciparum samples were obtained from four TES sentinel sites, Kibaha (Pwani), Mkuzi (Tanga), Mlimba (Morogoro), and Ujiji (Kigoma), between April and September 2016. Parasite genomic DNA was extracted from dried blood spots on filter papers using commercial kits. Genotyping was performed using six microsatellites (Poly-α, PfPK2, TA1, C3M69, C2M34 and 2490) by the capillary method, and the data were analyzed to determine the extent of polymorphisms and genetic diversity at the four sites.
Results Overall, 83 (88.3%) of the 94 samples were successfully genotyped (with positive results for ≥50.0% of the markers), and >50.0% (range = 47.6-59.1%) were polyclonal, with the mean multiplicity of infection ranging from 1.68 to 1.88 among the four sites. There was high genetic diversity but limited variability among the four sites based on mean allelic richness (RS = 7.48, range= 7.27- 8.03, for an adjusted minimum sample size of 18 per site) and mean expected heterozygosity (He = 0.83, range= 0.80-0.85). Cluster analysis of haplotypes using STRUCTURE, principal component analysis, and pairwise genetic differentiation (FST) did not detect any population structure, and isolates clustered independently of geographic origin. Of the six markers, Poly-α was the most polymorphic, followed by C2M34, TA1 and C3M69, while 2490 was the least polymorphic.
Conclusion Microsatellite genotyping revealed high polyclonality and genetic diversity but without any significant population structure. Poly-α, C2M34 and TA1 were the top polymorphic markers and could be adopted for use in TES in Tanzania.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by USAID under the US President’s Malaria Initiative (PMI) through MalariaCare (PATH). Laboratory analysis at CDC was supported by USAID/PMI through PARMA. The training fellowship to DSI in Australia was facilitated by BIO Ventures for Global Health (BVGH) through the WIPO Re:Search Fellowship Program with financial support from the Australian Government through Funds-in-Trust to the World Intellectual Property Organization (WIPO). DSI was also partly supported by the DELTAS Africa Initiative [grant 107740/Z/15/Z]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant 107740/Z/15/Z] and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance was obtained from the medical research coordinating committee (MRCC) of the National Institute for Medical Research (NIMR), while permission to conduct the study at the health facilities was sought in writing from the relevant regional and district medical authorities. Ethical clearance from the CDC was not needed because the assessments performed at the CDC Malaria Laboratory, using samples without linked identifiers (deidentified samples), were determined by the CDC Center of Global Health's Human Research Protection Coordinator to not constitute an engagement in human subjects' research. Informed consent (oral and written) was obtained from parents or guardians before patients were screened to assess their eligibility for possible inclusion in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The microsatellite data set used for this study is available and has been submitted with this paper as supplemental table 1. Additional prevalence data can be obtained from the NMCP upon making an official request.
